Penumbra PEN · NYSE
$325.11 +0.48% (+$1.55)
Summary
65 / 100 · Bulios Score
What speaks for it
- Revenue grew by 18% a year over the last 3 years.
- Out of every 100 USD of revenue, 11 USD is left as net profit.
- Analysts expect revenue to grow by 13% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 79.7 USD for 1 USD of yearly profit. Over the last five years it was 725.6 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 20% a year over 5 years. Over the last 3 years it grew by 18% a year. For the next fiscal year analysts expect revenue to grow by 13%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 32 USD
- Research and development 6.1 USD
- Sales and administration 49 USD
- Taxes and other 1.8 USD
- Net profit 11 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 9
- Hold 13
- Sell 0
Today's price within the analysts' price targets
The average target of $320 is 1.6% below today's price. 41% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2022By product
- Peripheral Vascular 59%
- Neuro 41%
By region
- UNITED STATES 78%
- Non-US 22%
Peripheral Vascular brings in 59% of revenue.
Segments in detail